Addendum
Vericiguat (cardiac failure) - Addendum to Commission A21-120
Report documents
-
Addendum
Vericiguat (cardiac failure) - Addendum to Commission A21-120
Dossier assessment
Indication:
Adults with symptomatic chronic heart failure with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy
Result of dossier assessment:
Unchanged after addendum:
- Age < 75 years: hint of a non-quantifiable added benefit
- Age ≥ 75 years: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-03-03 A G-BA decision was published.
Project details
- Project no.
- A22-08
- Commission
- Commission awarded on 25.01.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed